QPPV.COM KNOWLEDGE ASSESSMENT

GVP Module IX: Signal Outcomes and Regulatory Action — Knowledge Assessment

Test your understanding of the concepts covered by GVP Module IX: Signal Outcomes and Regulatory Action.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why must an organisation identify whether a product is centrally or nationally authorised before planning implementation of an EU signal recommendation?

Authorisation status determines whether the event is medically serious The applicable regulatory route and implementation pathway can differ by authorisation status Nationally authorised products are outside pharmacovigilance requirements Centrally authorised products do not require product-information control

Question 2 of 10 Which sequence best represents the controlled outcome-to-implementation model?

Scientific conclusion, implementation plan, signal validation, regulatory decision, closure Scientific conclusion, pharmacovigilance decision, regulatory assessment where applicable, implementation, verification, effectiveness or monitoring Regulatory decision, scientific conclusion, implementation, signal detection, effectiveness Implementation, product withdrawal, scientific assessment, monitoring, regulatory decision

Question 3 of 10 Under what circumstance might a previously closed signal appropriately be reopened?

Whenever an inspector asks about the historical issue When new cases, studies, literature, exposure changes or regulatory information materially alter the evidence Only when the original assessor is no longer employed Whenever any adverse event is reported, regardless of relevance

Question 4 of 10 A competent authority requests an additional analysis related to an ongoing signal assessment. What is the best way for the MAH to manage the analysis?

Treat it as an unrelated project and keep it separate from the signal record Identify the question, data and method, and integrate the result into the existing scientific and regulatory record Perform the analysis without documenting the methodology to avoid duplication Use the analysis to replace the entire original evidence base automatically

Question 5 of 10 Which statement best captures why signal management should not be judged by the number of regulatory changes it produces?

Regulatory changes are never relevant to signal management A mature system must distinguish signals requiring action from those for which evidence supports monitoring or documented no-action The number of signals detected is the only meaningful performance measure No-action decisions do not require governance

Question 6 of 10 What should an inspection-ready evidence chain demonstrate for a significant signal?

Only the final regulatory decision and the closure date A logical connection from detection and assessment through conclusion, decision, implementation, monitoring or effectiveness and closure or reassessment That all records are stored in one electronic database That every signal resulted in a formal regulatory measure

Question 7 of 10 Which statement best describes a legitimate no-further-action decision?

It means the signal was never scientifically assessed It is acceptable only when the association has been disproven beyond any doubt It may be appropriate when evidence and existing controls show that additional action is not currently justified It automatically means that routine pharmacovigilance can stop

Question 8 of 10 Which statement best reflects the role of regulatory action when scientific uncertainty remains?

Regulatory action is impossible until complete certainty is achieved Uncertainty may justify proportionate action, particularly for serious potential risks, provided the uncertainty is accurately described Any regulatory action establishes confirmed causality Uncertainty should be omitted from communications once action is taken

Question 9 of 10 A product-information change has been approved, but the implementation record does not show that the approved wording reached all required controlled documents. What is the most accurate assessment?

The scientific assessment is necessarily defective The regulatory decision is invalid because implementation was incomplete There is a traceability and implementation-control weakness No issue exists if the change was communicated verbally

Question 10 of 10 A signal assessment identifies a clinically important change in the frequency of an already recognised risk, while the risk itself is not new. What should the organisation do first?

Assume that no action is needed because the risk is already listed Determine the significance of the changed frequency and its implications for controls and benefit-risk Close the signal because only newly identified risks require assessment Replace the existing risk with an unrelated safety concern

GVP Module IX: Signal Outcomes and Regulatory Action — Knowledge Assessment

Cookie Settings